Type of article: review Title: Irisin is a Potential Novel Biomarker and
Therapeutic Target Against Kidney Diseases
- Xiu Huang,
- Xiya Ren,
- Limei Zhao,
- Yajie Hao,
- Zhibo Zhao,
- Fahui Chen,
- Jinxiu Zhou,
- Mengqi Bai,
- Si Chen,
- Xiaoshuang Zhou
Xiu Huang
Nephrology Department of Shanxi Provincial People’s Hospital
Author ProfileXiya Ren
Nephrology Department of Shanxi Provincial People’s Hospital
Author ProfileLimei Zhao
Nephrology Department of Shanxi Provincial People’s Hospital
Author ProfileYajie Hao
Nephrology Department of Shanxi Provincial People’s Hospital
Author ProfileZhibo Zhao
Nephrology Department of Shanxi Provincial People’s Hospital
Author ProfileJinxiu Zhou
Nephrology Department of Shanxi Provincial People’s Hospital
Author ProfileSi Chen
Nephrology Department of Shanxi Provincial People’s Hospital
Author ProfileAbstract
Kidney diseases, characterized by renal dysfunction, are among the
leading causes of death worldwide. Preventing and treating kidney
diseases is important for reducing their associated morbidity and
mortality. Moderate physical exercise has been recognized to be
advantageous for kidney health. Irisin is an exercise-induced myokine
identified in 2012. It plays an important role in energy and bone
metabolism, oxidative stress reduction, anti-inflammatory processes,
prevention of cell death, and cardiovascular protection. However, the
relationship between irisin and kidney disease has not been fully
elucidated. This review explores the role of irisin as a biomarker in
the diagnosis of kidney diseases and their associated complications,
elucidating the mechanisms through which it participates in various cell
death pathways, such as apoptosis, autophagy, pyroptosis and
ferroptosis. Furthermore, the levles of irisin secretion are discussed
to provide a basis for the preventing and treating kidney diseases, as
well as therapeutic guidance for developing new and promising
intervention strategies.29 Oct 2024Submitted to Cell Biochemistry & Function 04 Nov 2024Submission Checks Completed
04 Nov 2024Assigned to Editor
04 Nov 2024Review(s) Completed, Editorial Evaluation Pending
07 Nov 2024Reviewer(s) Assigned